Cesano A, Augustin R, Barrea L, Bedognetti D, Bruno T, Carturan A
J Immunother Cancer. 2025; 13(1).
PMID: 39824527
PMC: 11749597.
DOI: 10.1136/jitc-2024-008876.
Yoo S, Fitzgerald C, Cho B, Fitzgerald B, Han C, Koh E
Nat Med. 2025; .
PMID: 39762425
DOI: 10.1038/s41591-024-03398-5.
Tao D, Nardo M, Leung C, Lin H, Kang L, Le H
JAMA Netw Open. 2024; 7(11):e2447617.
PMID: 39585697
PMC: 11589797.
DOI: 10.1001/jamanetworkopen.2024.47617.
VanderVeen B, Cardaci T, Bullard B, Unger C, Freeman J, Enos R
Am J Physiol Cell Physiol. 2024; 328(1):C56-C77.
PMID: 39570672
PMC: 11901352.
DOI: 10.1152/ajpcell.00687.2024.
Nie W, Lu J, Qian J, Wang S, Cheng L, Zheng L
BMC Med. 2024; 22(1):463.
PMID: 39402614
PMC: 11475647.
DOI: 10.1186/s12916-024-03688-2.
Trem2 deficiency attenuates breast cancer tumor growth in lean, but not obese or weight loss, mice and is associated with alterations of clonal T cell populations.
Pierro E, Cottam M, An H, Lehmann B, Pietenpol J, Wellen K
bioRxiv. 2024; .
PMID: 39386686
PMC: 11463595.
DOI: 10.1101/2024.09.25.614811.
The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies.
Lysaght J, Conroy M
Nat Rev Endocrinol. 2024; 20(12):701-714.
PMID: 39313571
DOI: 10.1038/s41574-024-01032-5.
Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer.
Gomez-Banoy N, Ortiz E, Jiang C, Dagher C, Sevilla C, Girshman J
medRxiv. 2024; .
PMID: 38883775
PMC: 11178024.
DOI: 10.1101/2024.06.07.24308618.
Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox.
Vick L, Rosario S, Riess J, Canter R, Mukherjee S, Monjazeb A
NPJ Metab Health Dis. 2024; 2(1):5.
PMID: 38800540
PMC: 11116109.
DOI: 10.1038/s44324-024-00007-4.
Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.
Van Cauwenberge J, Van Baelen K, Maetens M, Geukens T, Nguyen H, Nevelsteen I
Breast Cancer Res. 2024; 26(1):81.
PMID: 38778365
PMC: 11112918.
DOI: 10.1186/s13058-024-01832-7.
Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk.
Piening A, Ebert E, Gottlieb C, Khojandi N, Kuehm L, Hoft S
Nat Commun. 2024; 15(1):2835.
PMID: 38565540
PMC: 10987624.
DOI: 10.1038/s41467-024-47359-5.
Clinical variables associated with immune checkpoint inhibitor outcomes in patients with metastatic urothelial carcinoma: a multicentre retrospective cohort study.
Labidi S, Meti N, Barua R, Li M, Riromar J, Jiang D
BMJ Open. 2024; 14(3):e081480.
PMID: 38553056
PMC: 10982788.
DOI: 10.1136/bmjopen-2023-081480.
Beyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance.
Bell H, Zou W
Annu Rev Immunol. 2024; 42(1):521-550.
PMID: 38382538
PMC: 11213679.
DOI: 10.1146/annurev-immunol-101819-024752.
Prognostic value of obesity in patients with cancer treated with immune checkpoint inhibitors: An updated meta‑analysis and systematic review.
Guo H, Lin X, Feng S, Wang C, Yuan L, Sheng X
Mol Clin Oncol. 2023; 20(1):5.
PMID: 38125744
PMC: 10729294.
DOI: 10.3892/mco.2023.2703.
The Influence of Obesity on Outcomes with Immune Checkpoint Blockade: Clinical Evidence and Potential Biological Mechanisms.
Hahn A, Venkatesh N, Msaouel P, McQuade J
Cells. 2023; 12(21).
PMID: 37947629
PMC: 10649394.
DOI: 10.3390/cells12212551.
Non-pharmaceutical interventions to optimize cancer immunotherapy.
Boesch M, Baty F, Rassouli F, Kowatsch T, Joerger M, Fruh M
Oncoimmunology. 2023; 12(1):2255459.
PMID: 37791231
PMC: 10543347.
DOI: 10.1080/2162402X.2023.2255459.
Signal detection in real-world data and confirmation in clinical trials: Diabetes as a case study for a conversation worth having.
Sharon E, Othus M, Quandt Z
Cancer. 2023; 129(18):2769-2770.
PMID: 37439269
PMC: 11060182.
DOI: 10.1002/cncr.34939.
Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy.
Yang K, Halima A, Chan T
Nat Rev Clin Oncol. 2023; 20(9):604-623.
PMID: 37328642
DOI: 10.1038/s41571-023-00789-4.
Early mortality in patients with cancer treated with immune checkpoint inhibitors in routine practice.
Raphael J, Richard L, Lam M, Blanchette P, Leighl N, Rodrigues G
J Natl Cancer Inst. 2023; 115(8):949-961.
PMID: 37195459
PMC: 10407698.
DOI: 10.1093/jnci/djad090.
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab.
Incorvaia L, Dimino A, Algeri L, Brando C, Magrin L, De Luca I
Front Oncol. 2023; 13:1141500.
PMID: 37139149
PMC: 10149939.
DOI: 10.3389/fonc.2023.1141500.
